Sign in

CIK 0001438533 · Large accelerated filer

Travere Therapeutics, Inc.

Sign in to watch
Ticker
TVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
CA
Entity type
operating
EIN
262383102
Phone
888-969-7879
Business address
3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
Former names
Retrophin, Inc., Desert Gateway, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$80,128,453
in 11 filings, $80.1M under 10b5-1 plans

Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
  2. Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
  3. ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
  4. Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
  5. Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2021-05-11 Rosenberg Noah L. Chief Medical Officer Sale −375 $19.14 $7K 45,969
2021-05-11 REED ELIZABETH E SVP, GC & Corporate Secretary Sale −1,625 $19.14 $31K 36,080
2021-05-11 Clague Laura Chief Financial Officer Sale −2,000 $19.14 $38K 30,223
2021-05-11 ASELAGE STEVE Director Sale −2,146 $19.58 $42K 186,794
2021-04-16 ASELAGE STEVE Director Option exercise +10,000 $16.23 $162K 198,940
2021-04-16 ASELAGE STEVE Director Sale −10,000 $26.23 $262K 188,940
2021-04-16 ASELAGE STEVE Director Option exercise · Employee stock option (right to buy) −10,000 140,000
2021-03-17 ASELAGE STEVE Director Option exercise +10,000 $16.23 $162K 206,667
2021-03-17 ASELAGE STEVE Director Sale −10,000 $27.35 $274K 196,667
2021-03-17 ASELAGE STEVE Director Sale −7,727 $27.56 $213K 188,940
2021-03-17 ASELAGE STEVE Director Option exercise · Employee stock option (right to buy) −10,000 150,000
2021-02-21 ASELAGE STEVE Director Option exercise · Employee stock option (right to buy) −25,000 275,000
2021-02-18 ROTE WILLIAM E. Senior Vice President, R&D Sale −1,250 $28.67 $36K 34,832
2021-02-17 ROTE WILLIAM E. Senior Vice President, R&D Sale −1,250 $27.35 $34K 36,082
2021-02-08 Rosenberg Noah L. Chief Medical Officer Sale −1,125 $31.58 $36K 46,344
2021-02-08 Heerma Peter Chief Commercial Officer Sale −1,125 $31.58 $36K 59,344
2021-02-08 ROTE WILLIAM E. Senior Vice President, R&D Sale −2,250 $31.58 $71K 37,332
2021-02-08 REED ELIZABETH E SVP, GC & Corporate Secretary Sale −2,250 $31.58 $71K 37,705
2021-02-08 Clague Laura Chief Financial Officer Sale −2,250 $31.58 $71K 32,223
2021-02-08 Dube Eric M Chief Executive Officer Sale −4,813 $31.58 $152K 156,813

Page 36 of 51 · 1,020 trades